Australia markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
92.60+1.23 (+1.35%)
At close: 4:00PM EDT
93.69 +1.09 (1.18%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close91.37
Bid90.87 x 1000
Ask93.80 x 800
Day's range92.29 - 92.87
52-week range63.22 - 92.87
Avg. volume925,396
Market cap212.345B
Beta (5Y monthly)0.29
PE ratio (TTM)31.61
EPS (TTM)2.93
Earnings dateN/A
Forward dividend & yield1.84 (2.02%)
Ex-dividend date26 Mar 2021
1y target est83.96
  • Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 26 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme initiat

  • Motley Fool

    Why Is Novo Nordisk Buying a Rare-Disease Candidate?

    Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.

  • Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall

    Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall

    Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.